藥明生物發盈喜股價續漲近4%再破頂 康希諾續漲11% 君實AH急漲20%及曾漲逾8%
藥明生物(02269.HK)發盈喜料中績多賺逾58%,該股今早曾升破7月13日盤中所創上市高位158.9元,最高見162元,現造155.5元,續升3.7%。
與美國藥廠輝瑞合作於中國推廣產品及明日將就科創板上市進行網上路演的康希諾生物(06185.HK)承昨天重越10天線勢,今天進一步升破20天線(223.85元),最高見251.4元,現造243.8元,續漲11%,成交增至4,909萬股,涉資11.84億元。此外,微創醫療(00853.HK)重越20天及10天線(39.4元),最高見41.15元,現造40.35元,回升4.5%。
君實生物(01877.HK)曾漲8.3%一舉重越10天及50天線(49.4元及51元),最高見52元,現造50.2元,升4.6%;君實A股(688180.SH)急漲20%報126.6元人民幣。
上海市新冠肺炎臨床救治專家組組長兼公共衛生專家組共同組長張文宏教授近期接受《財約你》專訪時表示,恢復期血漿和單克隆抗體是新冠特效藥,已在開展臨床研究,但產量有限。君實6月初曾宣布,與中國科學院微生物研究所共同開發重組全人源抗SARS-CoV-2單克隆抗體注射液已獲國家藥品監督管理局批准開展I期臨床研究並已完成首例受試者給藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.